Practice variation among Dutch paediatricians in palivizumab prescription rates: the importance of parental counselling approach

Acta Paediatr. 2019 Jul;108(7):1345-1349. doi: 10.1111/apa.14689. Epub 2019 Jan 15.

Abstract

Aim: To investigate differences in palivizumab prescription rates between Dutch paediatricians, and the role of parent counselling in this practice variation.

Methods: A retrospective chart review of premature infants <32 weeks of gestation, aged less than six months at the start of the winter season, born between January 2012 and July 2014, in three secondary hospital-based paediatric practices in the Netherlands.

Results: We included 208 patients, 133 (64%) of whom received palivizumab. Prescription rates varied considerably between the three hospitals: 8% (6/64), 89% (32/36) and 99% (97/98). A noticeable difference in the way parents were counselled about palivizumab was the use of the number needed to treat (NNT). In the hospital with the lowest prescription rate (8%), an NNT of 20 to prevent one hospitalisation was explicitly discussed with parents. Bronchiolitis-related hospital admissions occurred in 11.3% of patients receiving palivizumab compared to 20.0% in nonimmunised infants (p = 0.086).

Conclusion: Considerable practice variation exists among Dutch paediatricians regarding palivizumab prescription rates. The counselling method seems to play an important role. Presenting palivizumab prophylaxis as a preference-sensitive decision, combined with the explicit use and explanation of an NNT, leads many parents to refrain from respiratory syncytial virus immunisation.

Keywords: Bronchiolitis; Counselling; Number needed to treat; Palivizumab.

Publication types

  • Multicenter Study

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Bronchiolitis, Viral / prevention & control*
  • Counseling
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Netherlands
  • Palivizumab / therapeutic use*
  • Parents / psychology
  • Patient Admission / statistics & numerical data
  • Pediatrics / statistics & numerical data*
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Retrospective Studies

Substances

  • Antiviral Agents
  • Palivizumab